Patents by Inventor Jeffrey J Hale

Jeffrey J Hale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolidine modulators of CCR5 chemokine receptor activity
    Publication number: 20020094989
    Abstract: Pyrrolidine compounds of Formula I: 1
    Type: Application
    Filed: October 10, 2001
    Publication date: July 18, 2002
    Inventors: Jeffrey J. Hale, Christopher L. Lynch, Charles G. Caldwell, Christopher A. Willoughby, Dooseop Kim, Dong-Ming Shen, Sander G. Mills, Kevin T. Chapman, Liya Chen, Amy Gentry, Malcolm MacCoss, Zenon D. Konteatis
  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Publication number: 20020002164
    Abstract: Substituted heterocycles of the general structural formula: 1
    Type: Application
    Filed: April 17, 2001
    Publication date: January 3, 2002
    Applicant: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian John Williams
  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent number: 6235735
    Abstract: Substituted heterocycles of the general structural formula: are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: May 22, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Jeffrey J Hale, Paul E. Finke, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Tamara Ladduwahetty, Timothy Harrison, Brian John Williams
  • Pyrrolidine and piperidine modulators of chemokine receptor activity
    Patent number: 6166037
    Abstract: The present invention is directed to pyrrolidine and piperidine compounds of the formula I: ##STR1## (wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4a, R.sup.4b, R.sup.4c, R.sup.4d, R.sup.4e, R.sup.4f, R.sup.4g, R.sup.4h, m, n, x and y are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-1, CCR-2, CCR-2A, CCR-2B, CCR-3, CCR-4, CCR-5, CXCR-3, and/or CXCR-4.
    Type: Grant
    Filed: August 27, 1998
    Date of Patent: December 26, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Richard J. Budhu, Edward Holson, Jeffrey J. Hale, Christopher Lynch, Malcolm Maccoss, Scott C. Berk, Sander G. Mills, Christopher A. Willoughby
  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent number: 6048859
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: February 16, 1999
    Date of Patent: April 11, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian John Williams
  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent number: 5922706
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: July 13, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Tamara Ladduwahetty
  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent number: 5872116
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: October 28, 1997
    Date of Patent: February 16, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian John Williams
  • Spiro-substituted azacycles as tachykinin receptor antagonists
    Patent number: 5869496
    Abstract: Disclosed are spiro-substituted azacycles of formula (I), are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, emesis and asthma. In particular compounds of formula (I) are shown to be neurokinin antagonists.
    Type: Grant
    Filed: July 11, 1995
    Date of Patent: February 9, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills, Hongbo Qi, Shrenik K. Shah
  • Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
    Patent number: 5780467
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: July 14, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills
  • Morpholine and thiomorpholine tachykinin receptor antagonists
    Patent number: 5719147
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: February 17, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Paul E. Finke, Jeffrey J. Hale, Malcolm MacCoss, Sander G. Mills, Shrenik K. Shah, Mark Stuart Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian John Williams
  • Treatment of migraine with morpholine tachykinin receptor antagonists
    Patent number: 5716942
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: February 10, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Malcolm MacCoss, Jeffrey J. Hale, Sander G. Mills
  • Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
    Patent number: 5691336
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: November 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills
  • Process for preparing morpholine tachykinin receptor antagonists
    Patent number: 5637699
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: June 10, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Jeffrey J. Hale, Paul E. Finke, Malcolm MacCoss, Sander G. Mills, Shrenik K. Shah, Mark S. Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian J. Williams
  • Substituted azetidinones as anti-inflammatory and antidegenerative agents
    Patent number: 5591737
    Abstract: New substituted azetidinones of the general Formula (I) which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described. ##STR1## wherein R.sub.4 is (a) ##STR2## or (b) ##STR3## where R.sub.x is carboxy C.sub.1-6 alkyl, benzyloxycarbonylC.sub.1-3 alkyl, or t-butoxycarbonylC.sub.1-3 alkyl,whereinQ is a covalent bond or ##STR4## wherein R.sub.5 and R.sub.6 are each individually C.sub.1-3 alkyl or hydrogen,Y is ##STR5## or a covalent bond.
    Type: Grant
    Filed: December 16, 1993
    Date of Patent: January 7, 1997
    Assignee: Merck & Co., Inc.
    Inventors: James B. Doherty, Conrad P. Dorn, Philippe L. Durette, Paul E. Finke, Malcolm Maccoss, Sander G. Mills, Shrenik K. Shah, Soumya P. Sahoo, Jeffrey J. Hale, Thomas J. Lanza, William K. Hagmann
  • Treatment of emesis with morpholine tachykinin receptor antagonists
    Patent number: 5512570
    Abstract: Substituted heterocycles of the structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, emesis and nausea.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: April 30, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Malcolm MacCoss, Jeffrey J. Hale, Sander G. Mills
  • Process of making chiral 2-aryl-1,4-butanediamine derivatives as useful neurokinin-A antagonists
    Patent number: 5391819
    Abstract: Disclosed herein is a process of making chiral 2-aryl-1,4-butanediamine derivatives useful as neurokinin-A antagonists of Formula 7 ##STR1##
    Type: Grant
    Filed: September 30, 1992
    Date of Patent: February 21, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills